PMID- 37898338
OWN - NLM
STAT- MEDLINE
DCOM- 20231211
LR  - 20231217
IS  - 1872-8294 (Electronic)
IS  - 0169-409X (Linking)
VI  - 203
DP  - 2023 Dec
TI  - Emerging drug delivery systems with traditional routes - A roadmap to chronic 
      inflammatory diseases.
PG  - 115119
LID - S0169-409X(23)00434-9 [pii]
LID - 10.1016/j.addr.2023.115119 [doi]
AB  - Inflammation is prevalent and inevitable in daily life but can generally be 
      accommodated by the immune systems. However, incapable self-healing and 
      persistent inflammation can progress to chronic inflammation, leading to 
      prevalent or fatal chronic diseases. This review comprehensively covers the topic 
      of emerging drug delivery systems (DDSs) for the treatment of chronic 
      inflammatory diseases (CIDs). First, we introduce the basic biology of the 
      chronic inflammatory process and provide an overview of the main CIDs of the 
      major organs. Next, up-to-date information on various DDSs and the associated 
      strategies for ensuring targeted delivery and stimuli-responsiveness applied to 
      CIDs are discussed extensively. The implementation of traditional routes of drug 
      administration to maximize their therapeutic effects against CIDs is then 
      summarized. Finally, perspectives on future DDSs against CIDs are presented.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Min, Kiyoon
AU  - Min K
AD  - School of Materials Science and Engineering, Gwangju Institute of Science and 
      Technology (GIST), Gwangju 61005, Republic of Korea.
FAU - Sahu, Abhishek
AU  - Sahu A
AD  - Department of Biotechnology, National Institute of Pharmaceutical Education & 
      Research (NIPER), Hajipur, 844102, India.
FAU - Jeon, Sae Hyun
AU  - Jeon SH
AD  - School of Materials Science and Engineering, Gwangju Institute of Science and 
      Technology (GIST), Gwangju 61005, Republic of Korea.
FAU - Tae, Giyoong
AU  - Tae G
AD  - School of Materials Science and Engineering, Gwangju Institute of Science and 
      Technology (GIST), Gwangju 61005, Republic of Korea. Electronic address: 
      gytae@gist.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231028
PL  - Netherlands
TA  - Adv Drug Deliv Rev
JT  - Advanced drug delivery reviews
JID - 8710523
SB  - IM
MH  - Humans
MH  - *Drug Delivery Systems
MH  - *Inflammation/drug therapy
MH  - Chronic Disease
OTO - NOTNLM
OT  - Administration route
OT  - Chronic inflammatory disease
OT  - Drug delivery systems
OT  - Inflammation
OT  - Stimuli-responsive
OT  - Targeting
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/10/29 06:46
MHDA- 2023/12/11 12:43
CRDT- 2023/10/28 19:29
PHST- 2022/09/15 00:00 [received]
PHST- 2023/07/17 00:00 [revised]
PHST- 2023/10/23 00:00 [accepted]
PHST- 2023/12/11 12:43 [medline]
PHST- 2023/10/29 06:46 [pubmed]
PHST- 2023/10/28 19:29 [entrez]
AID - S0169-409X(23)00434-9 [pii]
AID - 10.1016/j.addr.2023.115119 [doi]
PST - ppublish
SO  - Adv Drug Deliv Rev. 2023 Dec;203:115119. doi: 10.1016/j.addr.2023.115119. Epub 
      2023 Oct 28.